|
1
|
Cos S, Martínez-Campa C, Mediavilla MD and
Sánchez-Barceló EJ: Melatonin modulates aromatase activity in MCF-7
human breast cancer cells. J Pineal Res. 38:136–142. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cos S, González A, Martínez-Campa C,
Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Melatonin
as a selective estrogen enzyme modulator. Curr Cancer Drug Targets.
8:691–702. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cos S, González A, Güezmes A, Mediavilla
MD, Martínez-Campa C, Alonso-González C and Sánchez-Barceló EJ:
Melatonin inhibits the growth of DMBA-induced mammary tumors by
decreasing the local biosynthesis of estrogens through the
modulation of aromatase activity. Int J Cancer. 118:274–278. 2006.
View Article : Google Scholar
|
|
4
|
Rato AG, Pedrero JG, Martínez MA, del Río
B, Lazo PS and Ramos S: Melatonin blocks the activation of estrogen
receptor for DNA binding. FASEB J. 13:857–868. 1999.PubMed/NCBI
|
|
5
|
Bouhoute A and Leclercq G: Calmodulin
decreases the estrogen binding capacity of the estrogen receptor.
Biochem Biophys Res Commun. 227:651–657. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
del Río B, García Pedrero JM,
Martínez-Campa C, Zuazua P, Lazo PS and Ramos S: Melatonin, an
endogenous‑specific inhibitor of estrogen receptor alpha via
calmodulin. J Biol Chem. 279:38294–38302. 2004. View Article : Google Scholar
|
|
7
|
Aronica SM, Kraus WL and Katzenellenbogen
BS: Estrogen action via the cAMP signaling pathway: Stimulation of
adenylate cyclase and cAMP-regulated gene transcription. Proc Natl
Acad Sci USA. 91:8517–8521. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Godson C and Reppert SM: The Mel1a
melatonin receptor is coupled to parallel signal transduction
pathways. Endocrinology. 138:397–404. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cos S and Blask DE: Melatonin modulates
growth factor activity in MCF-7 human breast cancer cells. J Pineal
Res. 17:25–32. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Molis TM, Spriggs LL, Jupiter Y and Hill
SM: Melatonin modulation of estrogen-regulated proteins, growth
factors, and proto-oncogenes in human breast cancer. J Pineal Res.
18:93–103. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cos S, Blask DE, Lemus‑Wilson A and Hill
AB: Effects of melatonin on the cell cycle kinetics and
'estrogen-rescue' of MCF-7 human breast cancer cells in culture. J
Pineal Res. 10:36–42. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alonso-González C, González A,
Martínez-Campa C, Menéndez-Menéndez J, Gómez-Arozamena J,
García-Vidal A and Cos S: Melatonin enhancement of the
radiosensitivity of human breast cancer cells is associated with
the modulation of proteins involved in estrogen biosynthesis.
Cancer Lett. 370:145–152. 2016. View Article : Google Scholar
|
|
13
|
Leon-Blanco MM, Guerrero JM, Reiter RJ,
Calvo JR and Pozo D: Melatonin inhibits telomerase activity in the
MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res.
35:204–211. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martínez-Campa CM, Alonso-González C,
Mediavilla MD, Cos S, González A and Sánchez-Barceló EJ: Melatonin
down-regulates hTERT expression induced by either natural estrogens
(17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human
breast cancer cells. Cancer Lett. 268:272–277. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cos S, Fernández R, Güézmes A and
Sánchez-Barceló EJ: Influence of melatonin on invasive and
metastatic properties of MCF-7 human breast cancer cells. Cancer
Res. 58:4383–4390. 1998.PubMed/NCBI
|
|
16
|
González A, Alvarez-García V,
Martínez-Campa C, Alonso-González C and Cos S: Melatonin promotes
differentiation of 3T3‑L1 fibroblasts. J Pineal Res. 52:12–20.
2012. View Article : Google Scholar
|
|
17
|
Alvarez-García V, González A,
Alonso-González C, Martínez-Campa C and Cos S: Melatonin interferes
in the desmoplastic reaction in breast cancer by regulating
cytokine production. J Pineal Res. 52:282–290. 2012. View Article : Google Scholar
|
|
18
|
Alvarez-García V, González A,
Martínez-Campa C, Alonso-González C and Cos S: Melatonin modulates
aromatase activity and expression in endothelial cells. Oncol Rep.
29:2058–2064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lissoni P, Barni S, Mandalà M, Ardizzoia
A, Paolorossi F, Vaghi M, Longarini R, Malugani F and Tancini G:
Decreased toxicity and increased efficacy of cancer chemotherapy
using the pineal hormone melatonin in metastatic solid tumour
patients with poor clinical status. Eur J Cancer. 35:1688–1692.
1999. View Article : Google Scholar
|
|
20
|
Lissoni P, Chilelli M, Villa S, Cerizza L
and Tancini G: Five years survival in metastatic non-small cell
lung cancer patients treated with chemotherapy alone or
chemotherapy and melatonin: A randomized trial. J Pineal Res.
35:12–15. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sookprasert A, Johns NP, Phunmanee A,
Pongthai P, Cheawchanwattana A, Johns J, Konsil J, Plaimee P,
Porasuphatana S and Jitpimolmard S: Melatonin in patients with
cancer receiving chemotherapy: A randomized, double-blind,
placebo-controlled trial. Anticancer Res. 34:7327–7337.
2014.PubMed/NCBI
|
|
22
|
Seely D, Wu P, Fritz H, Kennedy DA, Tsui
T, Seely AJ and Mills E: Melatonin as adjuvant cancer care with and
without chemotherapy: A systematic review and meta-analysis of
randomized trials. Integr Cancer Ther. 11:293–303. 2012. View Article : Google Scholar
|
|
23
|
Wang YM, Jin BZ, Ai F, Duan CH, Lu YZ,
Dong TF and Fu QL: The efficacy and safety of melatonin in
concurrent chemotherapy or radiotherapy for solid tumors: A
meta-analysis of randomized controlled trials. Cancer Chemother
Pharmacol. 69:1213–1220. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Reiter RJ, Rosales-Corral SA, Tan DX,
Acuña-Castroviejo D, Qin L, Yang SF and Xu K: Melatonin, a full
service anti-cancer agent: Inhibition of initiation, progression
and metastasis. Int J Mol Sci. 18:E8432017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martínez-Campa C, Menéndez-Menéndez J,
Alonso-González C, González A, Álvarez‑García V and Cos S: What is
known about melatonin, chemotherapy and altered gene expression in
breast cancer (Review). Oncol Lett. 13:2003–2014. 2017.
|
|
26
|
Xiang S, Dauchy RT, Hauch A, Mao L, Yuan
L, Wren MA, Belancio VP, Mondal D, Frasch T, Blask DE, et al:
Doxorubicin resistance in breast cancer is driven by light at
night-induced disruption of the circadian melatonin signal. J
Pineal Res. 59:60–69. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Granzotto M, Rapozzi V, Decorti G and
Giraldi T: Effects of melatonin on doxorubicin cytotoxicity in
sensitive and pleiotropically resistant tumor cells. J Pineal Res.
31:206–213. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Woo SM, Min KJ and Kwon TK:
Melatonin‑mediated Bim up-regulation and cyclooxygenase-2 (COX-2)
down-regulation enhances tunicamycin-induced apoptosis in
MDA-MB-231 cells. J Pineal Res. 58:310–320. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yun M, Kim EO, Lee D, Kim JH, Kim J, Lee
H, Lee J and Kim SH: Melatonin sensitizes H1975 non-small-cell lung
cancer cells harboring a T790M-targeted epidermal growth factor
receptor mutation to the tyrosine kinase inhibitor gefitinib. Cell
Physiol Biochem. 34:865–872. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Plaimee P, Weerapreeyakul N, Barusrux S
and Johns NP: Melatonin potentiates cisplatin-induced apoptosis and
cell cycle arrest in human lung adenocarcinoma cells. Cell Prolif.
48:67–77. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pariente R, Pariente JA, Rodríguez AB and
Espino J: Melatonin sensitizes human cervical cancer HeLa cells to
cisplatin-induced cytotoxicity and apoptosis: Effects on oxidative
stress and DNA fragmentation. J Pineal Res. 60:55–64. 2016.
View Article : Google Scholar
|
|
32
|
Uguz AC, Cig B, Espino J, Bejarano I,
Naziroglu M, Rodríguez AB and Pariente JA: Melatonin potentiates
chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic
tumor cells. J Pineal Res. 53:91–98. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma C, Li LX, Zhang Y, Xiang C, Ma T, Ma ZQ
and Zhang ZP: Protective and sensitive effects of melatonin
combined with adriamycin on ER+ (estrogen receptor)
breast cancer. Eur J Gynaecol Oncol. 36:197–202. 2015.
|
|
34
|
Koşar PA, Nazıroğlu M, Övey IS and Çiğ B:
Synergic effects of doxorubicin and melatonin on apoptosis and
mitochondrial oxidative stress in MCF-7 breast cancer cells:
Involvement of TRPV1 channels. J Membr Biol. 249:129–140. 2016.
View Article : Google Scholar
|
|
35
|
Rodríguez-García A, Mayo JC, Hevia D,
Quirós-González I, Navarro M and Sainz RM: Phenotypic changes
caused by melatonin increased sensitivity of prostate cancer cells
to cytokine-induced apoptosis. J Pineal Res. 54:33–45. 2013.
View Article : Google Scholar
|
|
36
|
Lee SE, Kim SJ, Youn JP, Hwang SY, Park CS
and Park YS: MicroRNA and gene expression analysis of
melatonin-exposed human breast cancer cell lines indicating
involvement of the anticancer effect. J Pineal Res. 51:345–352.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
39
|
Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ,
Ando A, Miyoshi Y, Maeda E, Noguchi S and Kato K: Prediction of
docetaxel response in human breast cancer by gene expression
profiling. J Clin Oncol. 23:422–431. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lumachi F, Chiara GB, Foltran L and Basso
SM: Proteomics as a guide for personalized adjuvant chemotherapy in
patients with early breast cancer. Cancer Genomics Proteomics.
12:385–390. 2015.PubMed/NCBI
|
|
41
|
Kiefer T, Ram PT, Yuan L and Hill SM:
Melatonin inhibits estrogen receptor transactivation and cAMP
levels in breast cancer cells. Breast Cancer Res Treat. 71:37–45.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
González A, Cos S, Martínez-Campa C,
Alonso-González C, Sánchez-Mateos S, Mediavilla MD and
Sánchez-Barcelo EJ: Selective estrogen enzyme modulator actions of
melatonin in human breast cancer cells. J Pineal Res. 45:86–92.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Vriend J and Reiter RJ: Breast cancer
cells: Modulation by melatonin and the ubiquitin-proteasome system
- a review. Mol Cell Endocrinol. 417:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nooshinfar E, Bashash D, Safaroghli-Azar
A, Bayati S, Rezaei-Tavirani M, Ghaffari SH and Akbari ME:
Melatonin promotes ATO-induced apoptosis in MCF-7 cells: Proposing
novel therapeutic potential for breast cancer. Biomed Pharmacother.
83:456–465. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Proietti S, Cucina A, Dobrowolny G,
D'Anselmi F, Dinicola S, Masiello MG, Pasqualato A, Palombo A,
Morini V, Reiter RJ, et al: Melatonin down-regulates MDM2 gene
expression and enhances p53 acetylation in MCF-7 cells. J Pineal
Res. 57:120–129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Berger C, Qian Y and Chen X: The
p53-estrogen receptor loop in cancer. Curr Mol Med. 13:1229–1240.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tiezzi DG, Andrade JM, Ribeiro-Silva A,
Zola FE, Marana HR and Tiezzi MG: HER-2, p53, p21 and hormonal
receptors proteins expression as predictive factors of response and
prognosis in locally advanced breast cancer treated with
neoadjuvant docetaxel plus epirubicin combination. BMC Cancer.
7:36–46. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mediavilla MD, Cos S and Sánchez-Barceló
EJ: Melatonin increases p53 and p21WAF1 expression in MCF‑7 human
breast cancer cells in vitro. Life Sci. 65:415–420. 1999.
View Article : Google Scholar
|
|
49
|
Elledge RM and Allred DC: Prognostic and
predictive value of p53 and p21 in breast cancer. Breast Cancer Res
Treat. 52:79–98. 1998. View Article : Google Scholar
|
|
50
|
Moelans CB, Verschuur-Maes AH and van
Diest PJ: Frequent promoter hypermethylation of BRCA2, CDH13, MSH6,
PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast
cancer. J Pathol. 225:222–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tudor G, Aguilera A, Halverson DO, Laing
ND and Sausville EA: Susceptibility to drug-induced apoptosis
correlates with differential modulation of Bad, Bcl-2 and Bcl-xL
protein levels. Cell Death Differ. 7:574–586. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Correia C, Lee SH, Meng XW, Vincelette ND,
Knorr KL, Ding H, Nowakowski GS, Dai H and Kaufmann SH: Emerging
understanding of Bcl-2 biology: Implications for neoplastic
progression and treatment. Biochim Biophys Acta. 1853:1658–1671.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mhaidat NM, Zhang XD, Jiang CC and Hersey
P: Docetaxel-induced apoptosis of human melanoma is mediated by
activation of c-Jun NH2-terminal kinase and inhibited by the
mitogen-activated protein kinase extracellular signal-regulated
kinase 1/2 pathway. Clin Cancer Res. 13:1308–1314. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Berchem GJ, Bosseler M, Mine N and
Avalosse B: Nanomolar range docetaxel treatment sensitizes MCF-7
cells to chemotherapy induced apoptosis, induces G2M arrest and
phosphorylates bcl-2. Anticancer Res. 19A:535–540. 1999.
|
|
55
|
Zang H, Li N, Pan Y and Hao J:
Identification of upstream transcription factors (TFs) for
expression signature genes in breast cancer. Gynecol Endocrinol.
33:193–198. 2017. View Article : Google Scholar
|
|
56
|
Abba MC, Nunez MI, Colussi AG, Croce MV,
Segal-Eiras A and Aldaz CM: GATA3 protein as a MUC1 transcriptional
regulator in breast cancer cells. Breast Cancer Res. 8:R642006.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Puttipanyalears C, Kitkumthorn N,
Buranapraditkun S, Keelawat S and Mutirangura A: Breast cancer
upregulating genes in stromal cells by LINE-1 hypermethylation and
micro-metastatic detection. Epigenomics. 8:475–486. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Girgert R, Hanf V, Emons G and Gründker C:
Membrane-bound melatonin receptor MT1 down-regulates estrogen
responsive genes in breast cancer cells. J Pineal Res. 47:23–31.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tamarkin L, Danforth D, Lichter A, DeMoss
E, Cohen M, Chabner B and Lippman M: Decreased nocturnal plasma
melatonin peak in patients with estrogen receptor positive breast
cancer. Science. 216:1003–1005. 1982. View Article : Google Scholar : PubMed/NCBI
|
